-
公开(公告)号：US11090386B2
公开(公告)日：2021-08-17
申请号：US16038710
申请日：2018-07-18
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Kentaro Nagane , Yosuke Ueki , Shusuke Sano , Takahisa Sakaguchi
Abstract: The present invention provides a method for suppressing bitterness of a quinoline derivative.
-
公开(公告)号：US20180318422A1
公开(公告)日：2018-11-08
申请号：US16038710
申请日：2018-07-18
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Kentaro Nagane , Yosuke Ueki , Shusuke Sano , Takahisa Sakaguchi
CPC classification number: A61K47/02 , A61K9/0095 , A61K9/10 , A61K31/47
Abstract: The present invention provides a method for suppressing bitterness of a quinoline derivative.
-
公开(公告)号：US20180263998A1
公开(公告)日：2018-09-20
申请号：US15516567
申请日：2015-10-08
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Yasuhiro Zaima , Kazuo Kazama , Shuntaro Arase , Kentaro Nagane , Kanta Horie , Yosuke Ueki
IPC: A61K31/542
CPC classification number: A61K31/542 , A61K9/2018 , A61K9/2054 , A61P25/28
Abstract: The present invention provides a pharmaceutical composition comprising a compound represented by formula (1): or N-[3-((4aS,5R,7aS)-2-amino-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxamide, or a pharmaceutically acceptable salt of the foregoing, and a salt of a compound having a C12-22 saturated aliphatic hydrocarbon group.
-
公开(公告)号：US09981040B2
公开(公告)日：2018-05-29
申请号：US14390854
申请日：2013-04-17
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Yosuke Ueki
IPC: A61K47/38 , A61K47/26 , A61K47/36 , A61K31/675 , A61K47/32 , A61K9/48 , A61K31/661 , A61K47/02
CPC classification number: A61K47/38 , A61K9/4816 , A61K9/4858 , A61K9/4891 , A61K31/661 , A61K31/675 , A61K47/02 , A61K47/26 , A61K47/32 , A61K47/36
Abstract: An object of the present invention is to provide a capsule formulation comprising a phosphonooxymethyl derivative of ravuconazole which suppresses delay in dissolution due to storage regardless of an encapsulated amount of the phosphonooxymethyl derivative of ravuconazole. The present invention provides a capsule formulation comprising an encapsulated material comprising {[(1R,2R)-2-[4-(4-cyanophenyl)-1,3-thiazol-2-yl]-1-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-ylmethyl)propyl]oxy}methyl dihydrogen phosphate or a pharmacologically acceptable salt thereof, or a solvate of any of the foregoing, and a capsule shell not comprising gelatin.
-
Patent Agency Ranking
公开(公告)号：US20180028662A1
公开(公告)日：2018-02-01
申请号：US15550124
申请日：2016-02-23
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Kentaro Nagane , Yosuke Ueki , Shusuke Sano , Takahisa Sakaguchi
CPC classification number: A61K47/02 , A61K9/0095 , A61K9/10 , A61K31/47
Abstract: The present invention provides a method for suppressing bitterness of a quinoline derivative.
-
公开(公告)号：US10117876B2
公开(公告)日：2018-11-06
申请号：US15516567
申请日：2015-10-08
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Yasuhiro Zaima , Kazuo Kazama , Shuntaro Arase , Kentaro Nagane , Kanta Horie , Yosuke Ueki
IPC: A61K31/542 , C07D513/04 , A61K9/20
CPC classification number: A61K31/542 , A61K9/2018 , A61K9/2054 , A61P25/28
Abstract: The present invention provides a pharmaceutical composition comprising a compound represented by formula (1): or N-[3-((4aS,5R,7aS)-2-amino-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d] [1,3]thiazin-7a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxamide, or a pharmaceutically acceptable salt of the foregoing, and a salt of a compound having a C12-22 saturated aliphatic hydrocarbon group.
-
公开(公告)号：US10076524B1
公开(公告)日：2018-09-18
申请号：US15516567
申请日：2015-10-08
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Yasuhiro Zaima , Kazuo Kazama , Shuntaro Arase , Kentaro Nagane , Kanta Horie , Yosuke Ueki
IPC: A61K31/542 , C07D513/04 , A61K9/20
CPC classification number: A61K31/542 , A61K9/2018 , A61K9/2054 , A61P25/28
Abstract: The present invention provides a pharmaceutical composition comprising a compound represented by formula (1): or N-[3-((4aS,5R,7aS)-2-amino-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d] [1,3]thiazin-7a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxamide, or a pharmaceutically acceptable salt of the foregoing, and a salt of a compound having a C12-22 saturated aliphatic hydrocarbon group.
-
公开(公告)号：US20150118299A1
公开(公告)日：2015-04-30
申请号：US14390854
申请日：2013-04-17
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Yosuke Ueki
CPC classification number: A61K47/38 , A61K9/4816 , A61K9/4858 , A61K9/4891 , A61K31/661 , A61K31/675 , A61K47/02 , A61K47/26 , A61K47/32 , A61K47/36
Abstract: An object of the present invention is to provide a capsule formulation comprising a phosphonooxymethyl derivative of ravuconazole which suppresses delay in dissolution due to storage regardless of an encapsulated amount of the phosphonooxymethyl derivative of ravuconazole. The present invention provides a capsule formulation comprising an encapsulated material comprising {[(1R,2R)-2-[4-(4-cyanophenyl)-1,3-thiazol-2-yl]-1-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-ylmethyl)propyl]oxy}methyl dihydrogen phosphate or a pharmacologically acceptable salt thereof, or a solvate of any of the foregoing, and a capsule shell not comprising gelatin.
Abstract translation: 本发明的目的是提供一种胶囊制剂，其包含拉夫康唑的膦酰氧甲基衍生物，其抑制由于储存而导致的溶解延迟，而不考虑拉夫康唑的膦酰氧甲基衍生物的包封量。 本发明提供了包含包含{[（1R，2R）-2- [4-（4-氰基苯基）-1,3-噻唑-2-基] -1-（2,4-二氟苯基） ）-1-（1H-1,2,4-三唑-1-基甲基）丙基]氧基}甲基二氢磷酸酯或其药学上可接受的盐，或任何上述溶剂合物，以及不包含明胶的胶囊壳。
-
公开(公告)号：US20140099366A1
公开(公告)日：2014-04-10
申请号：US14105373
申请日：2013-12-13
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Susumu Kimura , Yosuke Ueki , Masami Nohara , Yukifumi Dota
IPC: A61K47/38 , A61K31/13 , A61K31/445
CPC classification number: A61K47/38 , A61K9/2027 , A61K9/2054 , A61K9/209 , A61K9/2846 , A61K9/2866 , A61K9/5084 , A61K31/13 , A61K31/445 , A61K45/06 , A61K2300/00
Abstract: An object of the present invention is to provide, for the case of implementing a therapeutic method in which at least two kinds of anti-dementia drugs are used together, a composition that has a good therapeutic effect on dementia, and also gives excellent compliance. Another object of the present invention is to provide a composition containing at least two kinds of anti-dementia drugs, in which release of the anti-dementia drugs from the composition is controlled, whereby a combined effect of the anti-dementia drugs can be achieved well. Still another object of the present invention is to provide a composition for which the frequency of administration and the amount taken are reduced and hence compliance can be improved, and a method of manufacturing such a composition. According to the present invention, there is provided a composition containing at least two kinds of anti-dementia drugs; such a composition containing at least one sustained-release portion containing an anti-dementia drug; and such a composition containing at least one cholinesterase inhibitor, and at least one N-methyl-D-aspartate receptor antagonist.
Abstract translation: 本发明的目的是提供一种治疗方法，其中使用至少两种抗痴呆药物，对痴呆具有良好治疗效果的组合物，并且还具有优异的依从性。 本发明的另一个目的是提供一种含有至少两种抗痴呆药物的组合物，其中控制抗痴呆药物从组合物的释放，由此可以实现抗痴呆药物的组合效果 好。 本发明的另一个目的是提供一种组合物，其给药频率和使用量减少，因此可以提高顺应性，以及制备这种组合物的方法。 根据本发明，提供了含有至少两种抗痴呆药物的组合物， 这种组合物含有至少一种含有抗痴呆药物的缓释部分; 和含有至少一种胆碱酯酶抑制剂和至少一种N-甲基-D-天冬氨酸受体拮抗剂的组合物。
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.019 seconds)
